Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01006265 · ClinicalTrials.gov registry record · Phase 2
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
A Phase 2 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 2
- Development phase
- 464
- Enrollment target
NCT01006265 is a Phase 2 study that has completed, run by Actelion. The registered enrollment target is 464 participants.
The verdict
NCT01006265, a Phase 2 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 464 participants
- Enrollment target
Study Summary
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
Interventions
- DRUG Placebo
- DRUG ACT-128800 Dose 1
- DRUG ACT-128800 Dose 2
- DRUG ACT-128800 Dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2009-10-01 |
| Est. Completion | 2011-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01006265
The ClinicalTrials.gov registry entry for NCT01006265 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 464 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01006265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01006265 about?
NCT01006265 is a clinical study titled "Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis". This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
What is the current status of trial NCT01006265?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 464 participants. The study started on 2009-10-01. Estimated completion is 2011-07-01.
What interventions are being tested in trial NCT01006265?
The interventions under investigation include: Placebo (DRUG), ACT-128800 Dose 1 (DRUG), ACT-128800 Dose 2 (DRUG), ACT-128800 Dose 3 (DRUG).
Who is sponsoring clinical trial NCT01006265?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.